Effects of PPARγ agonists against vascular and renal dysfunction

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 248-254

  Sugawara, Akira ^a   Uruno, Akira ^a   Matsuda, Ken ^a   Saito Ito, Takako ^a   Funato, Tadao ^b   Saito Hakoda, Akiko ^a   Kudo, Masataka ^a   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU FUKUSHI UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Endothelium; Kidney; Thiazolidinediones; Thromboxane

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CYCLOSPORIN; DEOXYCORTICOSTERONE ACETATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE TRANSFERASE; KALLIKREIN 6; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN E RECEPTOR 1; ROSIGLITAZONE; STROMELYSIN 2; THROMBOXANE A2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TROGLITAZONE;

ADRENAL GLAND; AGING; ALDOSTERONE RELEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERIOLE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG INHIBITION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GLOMERULUS; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY INJURY; MEDIATOR; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEINURIA; RECEPTOR DOWN REGULATION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 84861745185     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020248     Document Type: Article

References (54)

1. Kliewer, S.A.; Xu, H.E.; Lambert, M.H.; Willson, T.M. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res., 2001, 56, 239-263.
2. Marchesi, C.; Schiffrin, E.L. Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects. J. Am. Soc. Hypertens., 2008, 2, 227-238.
3. Sarafidis, P.A.; Lasaridis, A.N. Actions of peroxisome proliferatoractivated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am. J. Hypertens., 2006, 19, 646-653.
4. Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefèbvre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R.G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R.J.; Korányi, L.; Laakso, M.; Mokán, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366, 1279-1289.
5. Sugawara, A.; Takeuchi, K.; Uruno, A.; Ikeda, Y.; Arima, S.; Kudo, M.; Sato, K.; Taniyama, Y.; Ito, S. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology, 2001, 142, 3125-3134.
6. Sugawara, A.; Takeuchi, K.; Uruno, A.; Ikeda, Y.; Arima, S.; Sato, K.; Kudo, M.; Taniyama, Y.; Ito, S. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens. Res., 2001, 24, 229-233.
7. Sugawara, A.; Takeuchi, K.; Uruno, A.; Kudo, M.; Sato, K.; Ito, S. Effects of mitogen-activated protein kinase pathway and coactivator CREB-binding protein on peroxisome proliferatoractivated receptor-gamma-mediated transcription suppression of angiotensin II type 1 receptor gene. Hypertens. Res., 2003, 26, 623-628.
8. Diep, Q.N.; El Mabrouk, M.; Cohn, J.S.; Endemann, D.; Amiri, F.; Virdis, A.; Neves, M.F.; Schiffrin, E.L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferatoractivated receptor-gamma. Circulation, 2002, 105, 2296-2302.
9. Benkirane, K.; Viel, E.C.; Amiri, F.; Schiffrin, E.L. Peroxisome proliferator-activated receptor gamma regulates angiotensin IIstimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension, 2006, 47, 102-108.
10. Ji, Y.; Liu, J.; Wang, Z.; Liu, N.; Gou, W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab. Invest., 2009, 89, 887-902.
11. Uruno, A.; Matsuda, K.; Noguchi, N.; Yoshikawa, T.; Kudo, M.; Satoh, F.; Rainey, W.E.; Hui, X. G.; Akahira, J.; Nakamura, Y.; Sasano, H.; Okamoto, H.; Ito, S.; Sugawara, A. Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. J. Mol. Endocrinol., 2011, 46, 37-49.
12. Wu, L.; Wang, R.; De Champlain, J.; Wilson, T.W. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am. J. Hypertens., 2004, 17, 749-756.
13. Iglarz, M.; Touyz, R.M.; Amiri, F.; Lavoie, M.F.; Diep, Q.N.; Schiffrin, E. L. Effect of peroxisome proliferator-activated receptor-alpha and-gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 45-51.
14. Ryan, M.J.; Didion, S.P.; Mathur, S.; Faraci, F.M.; Sigmund, C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension, 2004, 43, 661-666.
15. Tsai, Y.S.; Kim, H.J.; Takahashi, N.; Kim, H.S.; Hagaman, J.R.; Kim, J.K.; Maeda, N. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J. Clin. Invest., 2004, 114, 240-249.
16. Barroso, I.; Gurnell, M.; Crowley, V.E.; Agostini, M.; Schwabe, J.W.; Soos, M.A.; Maslen, G.L.; Williams, T.D.; Lewis, H.; Schafer, A.J.; Chatterjee, V.K.; O'Rahilly, S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 1999, 402, 880-883.
17. Tsai, Y.S.; Xu, L.; Smithies, O.; Maeda, N. Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure. Proc. Natl. Acad. Sci. USA, 2009, 106, 19084-19089.
18. Staels, B. PPARgamma and atherosclerosis. Curr. Med. Res. Opin., 2005, 21(Suppl. 1), S13-20.
19. Ikeda, Y.; Sugawara, A.; Taniyama, Y.; Uruno, A.; Igarashi, K.; Arima, S.; Ito, S.; Takeuchi, K. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2. J. Biol. Chem., 2000, 275, 33142-33150.
20. Sugawara, A.; Uruno, A.; Kudo, M.; Ikeda, Y.; Sato, K.; Taniyama, Y.; Ito, S.; Takeuchi, K. Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J. Biol. Chem., 2002, 277, 9676-9683.
21. Majithiya, J.B.; Paramar, A.N.; Balaraman, R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc. Res., 2005, 66, 150-161.
22. Miike, T.; Kunishiro, K.; Kanda, M.; Azukizawa, S.; Kurahashi, K.; Shirahase, H. Impairment of endothelium-dependent AChinduced relaxation in aorta of diabetic db/db mice--possible dysfunction of receptor and/or receptor-G protein coupling. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 377, 401-410.
23. Martens, F.M.; Visseren, F.L.; de Koning, E.J.; Rabelink, T.J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J. Cardiovasc. Pharmacol., 2005, 46, 773-778.
24. Staniloae, C.; Mandadi, V.; Kurian, D.; Coppola, J.; Bernaski, E.; El-Khally, Z.; Morlote, M.; Pinassi, E.; Ambrose, J. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology, 2007, 108, 164-169.
25. Beyer, A.M.; de Lange, W.J.; Halabi, C.M.; Modrick, M.L.; Keen, H.L.; Faraci, F.M.; Sigmund, C.D. Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ. Res., 2008, 103, 654-661.
26. Marx, N.; Walcher, D. Vascular effects of PPARgamma activators-from bench to bedside. Prog. Lipid Res., 2007, 46, 283-296.
27. Lim, S.; Jin, C.J.; Kim, M.; Chung, S.S.; Park, H.S.; Lee, I.K.; Lee, C.T.; Cho, Y.M.; Lee, H.K.; Park, K.S. PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 808-813.
28. Joner, M.; Farb, A.; Cheng, Q.; Finn, A.V.; Acampado, E.; Burke, A.P.; Skorija, K.; Creighton, W.; Kolodgie, F.D.; Gold, H.K.; Virmani, R. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 182-189.
29. Webb, D.R.; Davies, M.J.; Gray, L.J.; Abrams, K.R.; Srinivasan, B.; Das, S.; Taub, N.; Lawrence, I.; Sutton, S.; Khunti, K. Searching for the right outcome? A systematic review and metaanalysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. Diabetes Obes. Metab., 2010, 12, 124-132.
30. Kudo, M.; Sugawara, A.; Saito, A.; Uruno, A.; Ito, S. Effects of pioglitazone, belaprost, and fluvastatin on gene expression in vascular endothelial cells revealed by DNA microarray analyses. J. Hypertens., 2006, 24(Suppl. 6), 238.
31. Polikandriotis, J.A.; Mazzella, L.J.; Rupnow, H.L.; Hart, C.M. Peroxisome proliferator-activated receptor gamma agonists stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1810-1816.
32. Werner, C.; Kamani, C.H.; Gensch, C.; Böhm, M.; Laufs, U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes, 2007, 56, 2609-2615.
33. Kleinhenz, J.M.; Kleinhenz, D.J.; You, S.; Ritzenthaler, J.D.; Hansen, J.M.; Archer, D.R.; Sutliff, R.L.; Hart, C.M. Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am. J. Physiol. Heart. Circ. Physiol., 2009, 297, H1647-H1654.
34. Sutliff, R.L.; Kang, B.Y.; Hart, C.M. PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther. Adv. Respir. Dis., 2010, 4, 143-160.
35. Sato, K.; Sugawara, A.; Kudo, M.; Uruno, A.; Ito, S.; Takeuchi, K. Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertens. Res., 2004, 27, 417-425.
36. Ahn, K.O.; Lim, S.W.; Yang, H.J.; Li, C.; Sugawara, A.; Ito, S.; Choi, B.S.; Kim, Y.S.; Kim, J.; Yang, C.W. Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat. Yonsei Med. J., 2007, 48, 308-316.
37. Arima, S.; Kohagura, K.; Takeuchi, K.; Taniyama, Y.; Sugawara, A.; Ikeda, Y.; Abe, M.; Omata, K.; Ito, S. Biphasic vasodilator action of troglitazone on the renal microcirculation. J. Am. Soc. Nephrol., 2002, 13, 342-349.
38. Guan, Y.; Hao, C.; Cha, D.R.; Rao, R.; Lu, W.; Kohan, D.E.; Magnuson, M.A.; Redha, R.; Zhang, Y.; Breyer, M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med., 2005, 11, 861-866.
39. Yang, J.; Zhang, D.; Li, J.; Zhang, X.; Fan, F.; Guan, Y. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. Clin. Sci. (Lond), 2009, 116, 17-26.
40. Sarafidis, P.A.; Stafylas, P.C.; Georgianos, P.I.; Saratzis, A.N.; Lasaridis, A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am. J. Kidney Dis., 2010, 55, 835-847.
41. Chung, B.H.; Lim, S.W.; Ahn, K.O.; Sugawara, A.; Ito, S.; Choi, B.S.; Kim, Y.S.; Bang, B.K.; Yang, C.W. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology (Carlton), 2005, (Suppl. 10), S40-43.
42. Iglesias, P.; Díez, J.J. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol., 2006, 154, 613-621.
43. Chung, B.H.; Li, C.; Sun, B.K.; Lim, S.W.; Ahn, K.O.; Yang, J.H.; Choi, Y.H.; Yoon, K.H.; Sugawara, A.; Ito, S.; Kim, J.; Yang, C.W. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am. J. Transplant., 2005, 5, 1856-1867.
44. Yang, H.C.; Deleuze, S.; Zuo, Y.; Potthoff, S.A.; Ma, L.J.; Fogo, A.B. The PPARgamma agonist pioglitazone ameliorates agingrelated progressive renal injury. J. Am. Soc. Nephrol., 2009, 20, 2380-2388.
45. Yoshihara, D.; Kurahashi, H.; Morita, M.; Kugita, M.; Hiki, Y.; Aukema, H.M.; Yamaguchi, T.; Calvet, J.P.; Wallace, D.P.; Nagao, S. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am. J. Physiol. Renal. Physiol., 2011, 300, F465-474.
46. Zuo, Y.; Yang, H.C.; Potthoff, S.A.; Najafian, B.; Kon, V.; Ma, L.J.; Fogo, A.B. Protective effects of PPAR{gamma} agonist in acute nephrotic syndrome. Nephrol. Dial. Transplant., 2011 May 12. [Epub ahead of print]
47. Yoshioka, S.; Nishino, H.; Shiraki, T.; Ikeda, K.; Koike, H.; Okuno, A.; Wada, M.; Fujiwara, T.; Horikoshi H. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism, 1993, 42, 75-80.
48. Blanquicett, C.; Roman, J.; Hart, C.M. Thiazolidinediones as anticancer agents. Cancer Ther., 2008, 6, 25-34.
49. Yamauchi, A.; Takahashi, I.; Takasawa, S.; Nata, K.; Noguchi, N.; Ikeda, T.; Yoshikawa, T.; Shervani, N.J.; Suzuki, I.; Uruno, A.; Unno, M.; Okamoto, H.; Sugawara, A. Thiazolidinediones inhibit REG Ialpha gene transcription in gastrointestinal cancer cells. Biochem. Biophys. Res. Commun., 2009, 379, 743-748.
50. Suzuki, T.; Hayashi, S.; Miki, Y.; Nakamura, Y.; Moriya, T.; Sugawara, A.; Ishida, T.; Ohuchi, N.; Sasano, H. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Endocr. Relat. Cancer, 2006, 13, 233-250.
51. Nakamura, Y.; Suzuki, T.; Sugawara, A.; Arai, Y.; Sasano, H. Peroxisome proliferator-activated receptor gamma in human prostate carcinoma. Pathol. Int., 2009, 59, 288-293.
52. Palee, S.; Chattipakorn, S.; Phrommintikul, A.; Chattipakorn, N. PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? World. J. Cardiol., 2011, 3, 144-152.
53. Stephenson, J. Diabetes drug may be associated with increase in risk of bladder cancer. JAMA, 2011, 306, 143.
54. Sugawara, A.; Uruno, A.; Kudo, M.; Matsuda, K.; Yang, C.W.; Ito, S. Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease. Endocr. J., 2010, 57, 847-852.